| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
Neuraminidase (NA) (Km values for 4-MU-NANA range from 9.57 μM to 1780 μM across viral strains; kcat values range from 0.0257 s⁻¹ to 28.8 s⁻¹; catalytic efficiency kcat/Km ranges from 1.04 × 10³ M⁻¹s⁻¹ to 9.29 × 10⁵ M⁻¹s⁻¹)
|
|---|---|
| ln Vitro |
In vitro enzymatic assays using 4-MU-NANA showed that neuraminidase (NA) from the 2009 H1N1 pandemic virus (Cali09) exhibited low activity (kcat = 3.17 s⁻¹, Km = 37.3 μM, kcat/Km = 8.50 × 10⁴ M⁻¹s⁻¹), while NA from historical pandemic strains like A/Japan/305+/1957 (Japan57) had high activity (kcat = 28.8 s⁻¹, Km = 78.6 μM, kcat/Km = 3.66 × 10⁵ M⁻¹s⁻¹).
Swine virus NAs displayed variable activities: sw/Indiana00 NA had very low activity (kcat = 0.0257 s⁻¹, Km = 24.8 μM, kcat/Km = 1.04 × 10³ M⁻¹s⁻¹), whereas sw/Guangxi06 NA was highly efficient (kcat = 5.21 s⁻¹, Km = 9.57 μM, kcat/Km = 5.44 × 10⁵ M⁻¹s⁻¹). [1] Served as fluorescent substrate to screen NA inhibitors from 20 herbal medicines. Bupleurum chinense DC. extract exhibited strongest NA inhibition via fluorescence paper sensor. Identified saikosaponin a (IC50 = 177.3 μM), saikosaponin d (IC50 = 262.9 μM), and baicalin (IC50 = 241.4 μM) as bioactive inhibitors from Bupleurum chinense using affinity chromatography. [2] |
| Enzyme Assay |
In vitro enzymatic assays using 4-MU-NANA showed that neuraminidase (NA) from the 2009 H1N1 pandemic virus (Cali09) exhibited low activity (kcat = 3.17 s⁻¹, Km = 37.3 μM, kcat/Km = 8.50 × 10⁴ M⁻¹s⁻¹), while NA from historical pandemic strains like A/Japan/305+/1957 (Japan57) had high activity (kcat = 28.8 s⁻¹, Km = 78.6 μM, kcat/Km = 3.66 × 10⁵ M⁻¹s⁻¹).
Swine virus NAs displayed variable activities: sw/Indiana00 NA had very low activity (kcat = 0.0257 s⁻¹, Km = 24.8 μM, kcat/Km = 1.04 × 10³ M⁻¹s⁻¹), whereas sw/Guangxi06 NA was highly efficient (kcat = 5.21 s⁻¹, Km = 9.57 μM, kcat/Km = 5.44 × 10⁵ M⁻¹s⁻¹). [1] NA activity measured by hydrolysis of 4-MUNANA to fluorescent 4-MU. Optimized conditions: 50 μg/mL substrate, 30 min reaction, pH 7.5, 25°C in PBS buffer. Fluorescence quantified at ex=365 nm/em=445 nm. Paper sensor protocol: Test strips immersed in 4-MUNANA (50 μg/mL, 30 sec), reacted with NA. Fluorescence reduction under UV light (365 nm) indicated inhibition. [2] |
| References |
|
| Additional Infomation |
4-MU-NANA (2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid) is a synthetic fluorescent substrate for neuraminidase (NA) activity assays. Hydrolysis by NA releases 4-methylumbelliferone, enabling quantitative measurement of enzyme efficiency via fluorescence.
In this study, 4-MU-NANA was critical for demonstrating low NA activity in the 2009 H1N1 pandemic virus, which contributed to a functional HA-NA balance essential for human transmission. [1] 4-MUNANA (4-methylumbelliferyl-N-acetylneuraminic acid) is a fluorogenic substrate for neuraminidase (NA). Hydrolysis releases 4-methylumbelliferone (4-MU), enabling real-time NA activity monitoring. Integrated with magnetic affinity chromatography for high-throughput inhibitor screening from herbal complexes. Method validated with zanamivir (positive control, IC50 = 79.52 μM). |
| Molecular Formula |
C21H24NO11-.NA+
|
|---|---|
| Molecular Weight |
489.40516
|
| Exact Mass |
489.124
|
| CAS # |
76204-02-9
|
| PubChem CID |
23683295
|
| Appearance |
White to light yellow solid powder
|
| Melting Point |
171ºC dec.
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
808
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC1=CC(=O)OC2=C1C=CC(=C2)O[C@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)[O-].[Na+]
|
| InChi Key |
NNNXBDLJYKMDAI-BUIQBYSTSA-M
|
| InChi Code |
InChI=1S/C21H25NO11.Na/c1-9-5-16(27)31-15-6-11(3-4-12(9)15)32-21(20(29)30)7-13(25)17(22-10(2)24)19(33-21)18(28)14(26)8-23;/h3-6,13-14,17-19,23,25-26,28H,7-8H2,1-2H3,(H,22,24)(H,29,30);/q;+1/p-1/t13-,14+,17+,18+,19+,21-;/m0./s1
|
| Chemical Name |
sodium;(2R,4S,5R,6R)-5-acetamido-4-hydroxy-2-(4-methyl-2-oxochromen-7-yl)oxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate
|
| Synonyms |
76204-02-9; 2'-(4-Methylumbelliferyl)-alpha-D-N-acetylneuraminic acid, sodium salt; sodium;(2R,4S,5R,6R)-5-acetamido-4-hydroxy-2-(4-methyl-2-oxochromen-7-yl)oxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate; N-Acetyl-2-O-(4-Methylumbelliferyl)-alpha-D-neuraminic Acid Sodium Salt; 2'-(4-Methylumbelliferyl)-?-D-N-acetylneuraminic Acid Sodium Salt; 4-MU-NANA⋅Na; Neu5Ac- alpha -4MU; Sodium 2-(4-methylumbelliferyl)-N-acetylneuraminate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~510.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0433 mL | 10.2164 mL | 20.4328 mL | |
| 5 mM | 0.4087 mL | 2.0433 mL | 4.0866 mL | |
| 10 mM | 0.2043 mL | 1.0216 mL | 2.0433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
